5 Stocks Underperforming Today In The Drugs Industry

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 34 points (-0.2%) at 15,991 as of Tuesday, Dec. 10, 2013, 11:45 AM ET. The NYSE advances/declines ratio sits at 1,256 issues advancing vs. 1,637 declining with 176 unchanged.

The Drugs industry currently sits down 0.7% versus the S&P 500, which is down 0.2%. A company within the industry that fell today was Sanofi ( SNY), up 1.1%.

TheStreet would like to highlight 5 stocks pushing the industry lower today:

5. Novo Nordisk A/S ( NVO) is one of the companies pushing the Drugs industry lower today. As of noon trading, Novo Nordisk A/S is down $2.00 (-1.1%) to $177.62 on light volume. Thus far, 83,951 shares of Novo Nordisk A/S exchanged hands as compared to its average daily volume of 285,100 shares. The stock has ranged in price between $177.47-$178.54 after having opened the day at $178.19 as compared to the previous trading day's close of $179.61.

Novo Nordisk A/S engages in the discovery, development, manufacture, and marketing of pharmaceutical products primarily in Denmark. It operates in two segments, Diabetes Care and Biopharmaceuticals. Novo Nordisk A/S has a market cap of $98.3 billion and is part of the health care sector. The company has a P/E ratio of 4.0, below the S&P 500 P/E ratio of 17.7. Shares are up 9.5% year to date as of the close of trading on Monday. Currently there is 1 analyst that rates Novo Nordisk A/S a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Novo Nordisk A/S as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Novo Nordisk A/S Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

4. As of noon trading, GlaxoSmithKline ( GSK) is down $0.55 (-1.1%) to $51.96 on light volume. Thus far, 812,360 shares of GlaxoSmithKline exchanged hands as compared to its average daily volume of 2.5 million shares. The stock has ranged in price between $51.92-$52.24 after having opened the day at $52.11 as compared to the previous trading day's close of $52.51.

GlaxoSmithKline plc, together with its subsidiaries, discovers, develops, manufactures, and markets pharmaceutical products, over-the-counter medicines, and health-related consumer products worldwide. GlaxoSmithKline has a market cap of $127.9 billion and is part of the health care sector. The company has a P/E ratio of 15.9, below the S&P 500 P/E ratio of 17.7. Shares are up 20.8% year to date as of the close of trading on Monday. Currently there are 2 analysts that rate GlaxoSmithKline a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates GlaxoSmithKline as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations, increase in stock price during the past year, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full GlaxoSmithKline Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Gilead ( GILD) is down $1.20 (-1.6%) to $73.99 on average volume. Thus far, 5.7 million shares of Gilead exchanged hands as compared to its average daily volume of 8.9 million shares. The stock has ranged in price between $73.53-$75.10 after having opened the day at $75.00 as compared to the previous trading day's close of $75.19.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Gilead has a market cap of $113.5 billion and is part of the health care sector. The company has a P/E ratio of 40.6, above the S&P 500 P/E ratio of 17.7. Shares are up 104.7% year to date as of the close of trading on Monday. Currently there are 16 analysts that rate Gilead a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, reasonable valuation levels, expanding profit margins and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Gilead Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Merck ( MRK) is down $0.32 (-0.7%) to $49.24 on light volume. Thus far, 3.8 million shares of Merck exchanged hands as compared to its average daily volume of 14.1 million shares. The stock has ranged in price between $49.10-$49.48 after having opened the day at $49.29 as compared to the previous trading day's close of $49.56.

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide. Merck has a market cap of $144.3 billion and is part of the health care sector. The company has a P/E ratio of 33.1, above the S&P 500 P/E ratio of 17.7. Shares are up 21.1% year to date as of the close of trading on Monday. Currently there are 5 analysts that rate Merck a buy, 1 analyst rates it a sell, and 8 rate it a hold.

TheStreet Ratings rates Merck as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Merck Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Pfizer ( PFE) is down $0.30 (-0.9%) to $31.28 on light volume. Thus far, 8.4 million shares of Pfizer exchanged hands as compared to its average daily volume of 25.3 million shares. The stock has ranged in price between $31.20-$31.49 after having opened the day at $31.41 as compared to the previous trading day's close of $31.58.

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells medicines for people and animals worldwide. Pfizer has a market cap of $204.4 billion and is part of the health care sector. The company has a P/E ratio of 20.9, above the S&P 500 P/E ratio of 17.7. Shares are up 25.9% year to date as of the close of trading on Monday. Currently there are 8 analysts that rate Pfizer a buy, 1 analyst rates it a sell, and 3 rate it a hold.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, increase in stock price during the past year, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Pfizer Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%